Thermo Fisher Scientific Inc. (NYSE:TMO – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-nine brokerages that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating, twenty-three have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $683.64.
A number of equities research analysts recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $630.00 price objective (up from $585.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Sanford C. Bernstein increased their target price on Thermo Fisher Scientific from $520.00 to $575.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Wells Fargo & Company cut Thermo Fisher Scientific from an “overweight” rating to an “underweight” rating in a report on Wednesday, September 9th. Citigroup boosted their target price on Thermo Fisher Scientific from $685.00 to $800.00 and gave the stock a “buy” rating in a research report on Friday, October 23rd. Finally, The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $650.00 to $780.00 and gave the stock a “buy” rating in a research report on Monday, September 21st.
Read Our Latest Stock Analysis on TMO
Key Thermo Fisher Scientific News
These are some of the TMO news items that stood out recently:
- Positive Sentiment: A Sound Shore Management investor letter describes Thermo Fisher as near a cyclical bottom, with potential to re-accelerate toward historical growth. That outlook may support sentiment, though it is an investor’s assessment rather than company guidance. Article: Thermo Fisher Scientific cyclical bottom signals re-acceleration
- Positive Sentiment: Industry reports forecast substantial growth in markets where Thermo Fisher competes, including single-use bioprocessing, cell lysis and fractionation, and cell-culture coatings. These projections point to potential demand tailwinds, but are third-party market estimates, not company-specific forecasts. Article: Single-use bioprocessing market report Article: Cell lysis and fractionation market report Article: Cell culture protein surface coating market report
- Neutral Sentiment: A recent analysis revisits Thermo Fisher’s $5 billion buyback and cash generation after strong multiyear share gains. The buyback supports capital returns, while the discussion highlights the need for future cash flows to justify expectations; the article excerpt gives no new buyback details or firm valuation conclusion. Article: Is Thermo Fisher reasonable after its $5 billion buyback?
Insider Buying and Selling
In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the sale, the vice president directly owned 14,784 shares in the company, valued at approximately $9,064,366.08. This trade represents a 43.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total transaction of $6,292,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,982,284.75. This represents a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 24,546 shares of company stock valued at $15,479,192. Corporate insiders own 0.33% of the company’s stock.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Legacy Wealth Managment LLC ID raised its position in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock worth $25,000 after purchasing an additional 22 shares during the period. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $25,000. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at approximately $26,000. Compass Financial Management LLC increased its stake in Thermo Fisher Scientific by 137.5% during the 3rd quarter. Compass Financial Management LLC now owns 38 shares of the medical research company’s stock worth $26,000 after purchasing an additional 22 shares in the last quarter. Finally, Pingora Partners LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $30,000. 89.23% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Trading Up 0.1%
Shares of TMO traded up $0.54 on Friday, reaching $699.98. 1,837,337 shares of the company’s stock were exchanged, compared to its average volume of 2,259,394. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $259.36 billion, a P/E ratio of 36.92, a price-to-earnings-growth ratio of 2.85 and a beta of 0.84. The business has a 50 day moving average price of $670.82 and a two-hundred day moving average price of $556.81. Thermo Fisher Scientific has a 12 month low of $435.27 and a 12 month high of $727.56.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its quarterly earnings data on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the firm earned $5.79 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Research analysts anticipate that Thermo Fisher Scientific will post 25.27 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 15th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 9.92%.
About Thermo Fisher Scientific
Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.
See Also
- Five stocks we like better than Thermo Fisher Scientific
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
